What this means for cost
Retatrutide has no price: it is not approved, and anything sold online as retatrutide today is not Lilly's drug. The approved medicines closest to it are tirzepatide and semaglutide. These are today's prices, from the makers' self-pay pages and the dated reads on our board.
- Zepbound (tirzepatide) from Lilly, self-pay$299 to $449/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Cheapest compounded tirzepatide$69/moat Wellmedr, sale price, all inWellmedr: plans and pricesRead 22 Nov 2026. Compounded, not FDA-approved.
- Wegovy (semaglutide) from Novo, self-pay$199 to $399/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Cheapest compounded semaglutide$39/moat Wellmedr, sale price, all inWellmedr: plans and pricesRead 22 Nov 2026. Compounded, not FDA-approved.
Compounded drugs are not FDA-approved.
What happens next
- Q1 2027Lilly plans to submit retatrutide to the FDA for US approval (a Biologics License Application).
- After filingFDA review. Lilly has not given a decision date; we will add it when one is published.
Sources
- Eli Lilly, TRIUMPH-1 topline results (May 21, 2026), read 20 Nov 2026
- Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results and Q1 2027 filing plan (Jul 23, 2026), read 20 Nov 2026
- Eli Lilly, TRIUMPH-2 detailed results (Sep 29, 2026), read 20 Nov 2026
- Eli Lilly press releases, including TRANSCEND-T2D-2 (Oct 28, 2026), read 20 Nov 2026




